Search hospitals > Tennessee > Nashville
Sarah Cannon Cancer Center
Claim this profileNashville, Tennessee 37203
Global Leader in Tumors
Global Leader in Solid Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
219 reported clinical trials
14 medical researchers
Summary
Sarah Cannon Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Tumors, Solid Tumors, Non-Small Cell Lung Cancer, Breast Cancer, Cancer and other specialties. Sarah Cannon Cancer Center is involved with conducting 219 clinical trials across 155 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and Gerald Falchook, MD.Area of expertise
1Tumors
Global LeaderStage IV
Stage III
FGFR3 positive
2Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
59 reported clinical trials
86 drugs studied
Erika P HamiltonSarah Cannon Research Institute4 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
53 reported clinical trials
76 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Solid Tumors
Expert in Tumors
34 reported clinical trials
66 drugs studied
Gerald Falchook, MDSarah Cannon Research Institute at HealthONE5 years of reported clinical research
Expert in Tumors
Expert in Solid Tumors
37 reported clinical trials
58 drugs studied
Clinical Trials running at Sarah Cannon Cancer Center
Breast Cancer
Solid Tumors
Prostate Cancer
Tumors
Pancreatic Cancer
Cancer
Non-Small Cell Lung Cancer
Melanoma
Lung Cancer
Renal Cell Carcinoma
Atezolizumab + Trastuzumab Emtansine
for Breast Cancer
This study is evaluating whether a drug may help reduce the risk of cancer returning in patients with HER2-positive breast cancer.
Recruiting1 award Phase 35 criteria
TAK-500 + Pembrolizumab
for Advanced Solid Cancers
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.
Recruiting1 award Phase 1 & 213 criteria
ST101
for Advanced Cancer
This study is evaluating whether a drug may help treat solid tumors.
Recruiting1 award Phase 1 & 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sarah Cannon Cancer Center?
Sarah Cannon Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Tumors, Solid Tumors, Non-Small Cell Lung Cancer, Breast Cancer, Cancer and other specialties. Sarah Cannon Cancer Center is involved with conducting 219 clinical trials across 155 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and Gerald Falchook, MD.